How does Moderna's mRNA flu vaccine work?

The U.S. Food and Drug Administration (FDA) has approved Moderna's first mRNA-based flu vaccine, marking a significant advancement in influenza prevention. This approval signifies the broader application of mRNA technology, previously known for its role in COVID-19 vaccines, to combat seasonal influenza. The vaccine, known as mFlusiva, is designed to protect against the most common strains of the flu virus.

The Background: A New Era for Vaccine Technology

The development of mRNA vaccines represents a paradigm shift from traditional vaccine methods. For decades, flu vaccines have been produced using a process that involves growing the influenza virus in fertilized chicken eggs or cell cultures. This method can take several months, often leading to a mismatch between the vaccine strains and the circulating flu strains by the time the vaccine is ready for distribution. The COVID-19 pandemic accelerated the development and widespread adoption of mRNA vaccine technology, demonstrating its speed and adaptability. Moderna's success with its COVID-19 vaccine paved the way for applying this platform to other infectious diseases, including influenza. The FDA's approval of mFlusiva follows a period of review, including an initial refusal-to-file notice, indicating the rigorous evaluation process for novel vaccine technologies.

The Mechanism: mRNA's Precision Approach

Unlike traditional vaccines that introduce a weakened or inactivated virus, or parts of it, mRNA vaccines work by instructing the body's cells to produce a specific protein. In the case of mFlusiva, the vaccine contains messenger RNA (mRNA) molecules that carry the genetic code for a key component of the influenza virus, typically the hemagglutinin (HA) protein. Once injected, the mRNA enters the body's cells, and the cellular machinery reads the genetic instructions to produce the HA protein. The immune system then recognizes this protein as foreign and mounts a response, creating antibodies. If the vaccinated individual is later exposed to the actual flu virus, their immune system is prepared to quickly neutralize it, preventing or reducing the severity of infection. A key advantage of this mRNA approach is its speed; once the genetic sequence of a new flu strain is known, an mRNA vaccine can be designed and produced much faster than traditional methods, potentially allowing for more timely updates to match circulating strains.

Who is Affected and How, Concretely

This approval directly impacts individuals seeking protection against seasonal influenza, offering a new vaccine option with potentially enhanced efficacy and faster adaptability. For healthcare providers and public health officials, it introduces a new tool in the fight against the flu, one that could improve vaccination rates and reduce the burden of seasonal illness. The speed at which mRNA vaccines can be developed means that future flu vaccines could be more precisely tailored to the strains predicted to be most prevalent in a given season, potentially leading to better protection. This could translate to fewer flu-related hospitalizations, doctor's visits, and lost work or school days. For individuals with egg allergies, who previously faced limitations with some flu vaccines, mRNA technology offers an alternative that does not rely on egg-based production.

What Happens Next, and What Would Have to Be True

Following FDA approval, Moderna can now commercialize mFlusiva for the upcoming flu season. The next steps involve widespread manufacturing, distribution, and recommendation by public health authorities like the Centers for Disease Control and Prevention (CDC). For the vaccine to become a significant player, it needs to demonstrate clear advantages in real-world effectiveness compared to existing flu vaccines, such as higher efficacy rates or better protection against specific strains. Widespread adoption will also depend on its inclusion in public health vaccination campaigns and insurance coverage. If mFlusiva proves to be highly effective and adaptable, it could gradually shift the landscape of influenza prevention, making mRNA technology the standard for flu vaccines. Conversely, if it shows no significant improvement over existing vaccines or faces manufacturing or distribution challenges, its impact may be limited. The long-term success will also depend on continued surveillance of flu strains and the ability of the mRNA platform to be rapidly updated to match evolving viruses.